Post-RP imaging modality yields disappointing results

Orlando, FL-Among patients who undergo radiation treatment forprostate cancer following biochemical failure post-prostatectomy, use ofthe ProstaScint immunoscintigraphy scan appears to fail at reliably locatingdisease, researchers reported at the AUA annual meeting.

Related Videos

Related Content

Advertisement

October 11th 2024

Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer

Hannah Clarke

“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

October 11th 2024

Biomarker may predict MIBC status following neoadjuvant chemo

Elizabeth R. Plimack, MD, MS, FASCO

"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

October 10th 2024

How to code for cystoscopy with litholapaxy of more than 40 bladder calculi

Jonathan Rubenstein, MD Mark Painter

"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter.

October 10th 2024

Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting

Urology Times staff

"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO.

Related Content

Advertisement

October 11th 2024

Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer

Hannah Clarke

“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

October 11th 2024

Biomarker may predict MIBC status following neoadjuvant chemo

Elizabeth R. Plimack, MD, MS, FASCO

"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

October 10th 2024

How to code for cystoscopy with litholapaxy of more than 40 bladder calculi

Jonathan Rubenstein, MD Mark Painter

"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter.

October 10th 2024

Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting

Urology Times staff

"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO.